Table 1. Clinical characteristics of patients treated with PrOD.
| Characteristic | Total | Hepatic decompensation | P value | |
|---|---|---|---|---|
| (n = 189) | No (n = 184) | Yes (n = 5) | ||
| Age, years | 65.2±9.1 | 64.9±8.9 | 78.3±6.9 | 0.001 |
| Gender (male), % | 78 (41.3) | 76 (41.3) | 2 (40.0) | 1.0 |
| Treatment-experienced, % | 151 (79.9) | 148 (80.4) | 3 (60.0) | 0.264 |
| CTP at entry, % | 0.196 | |||
| 5 | 181 (95.8) | 177 (96.2) | 4 (80.0) | |
| 6 | 8 (4.2) | 7 (3.8) | 1 (20.0) | |
| METAVIR score | 1.000 | |||
| F3 | 77 (40.7) | 75 (40.8) | 2 (40.0) | |
| F4 | 112 (59.3) | 109 (59.2) | 3 (60.0) | |
| HCC status at entry, % | 48 (25.4) | 45 (24.5) | 3 (60.0) | 0.105 |
| Cure | 36 (19.0) | 33 (17.9) | 3 (60.0) | |
| Active | 9 (4.8) | 9 (4.9) | 0 (0) | |
| Baseline data | ||||
| Biochemistry | ||||
| Albumin (g/dL) | 4.2±0.4 | 4.2±0.4 | 3.6±0.1 | < 0.001 |
| >3.6 | 172 (91.0) | 170 (92.4) | 2 (30.0) | 0.005 |
| ≤3.6 | 17 (9.0) | 14 (7.6) | 6 (60.0) | |
| AST (U/L) | 88±49 | 89±53 | 70±27 | 0.448 |
| ALT (U/L) | 96±59 | 98±65 | 54±15 | 0.134 |
| Bilirubin (mg/dL) | ||||
| Total form | 0.84±0.33 | 0.84±0.33 | 0.86±0.11 | 0.939 |
| Direct form | 0.33±0.18 | 0.33±0.18 | 0.33±0.05 | 0.981 |
| Indirect form | 0.53±0.28 | 0.53±0.29 | 0.53±0.13 | 0.991 |
| Platelet (1000/μL) | 129±53 | 129±53 | 141±74 | 0.618 |
| INR | 1.10±0.08 | 1.10±0.08 | 1.12±0.04 | 0.622 |
| FIB-4 | 5.62±3.98 | 5.36±3.75 | 6.22±3.22 | 0.581 |
| HCV RNA (log10 IU/mL) | 6.22±0.59 | 6.23±0.59 | 5.84±0.38 | 0.138 |
| EOTVR, % | 184 (97.4) | 184 (100) | NA | |
| SVR12, % | 109/112 (97.3) | 107/109 (98.2) | 2/3 (66.7) | 0.079 |
PrOD = paritaprevir/ritonavir/ombitasvir plus dasabuvir; CTP = Child-Turcotte-Pugh score; AST = aspartate aminotransferase; ALT = alanine transaminase; INR = international normalized ratio; FIB-4 = Fibrosis-4 score; HCC = hepatocellular carcinoma; HCV RNA = hepatitis C virus ribonucleic acid; EOTVR = end-of-treatment virologic response; SVR12 = sustained virologic response at 12 weeks after treatment; NA = not available.